Literature DB >> 23900138

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

R C Prins1, R T Burke, J W Tyner, B J Druker, M M Loriaux, S E Spurgeon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23900138     DOI： 10.1038/leu.2013.228

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  27 in total

Review 1.  The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia.

Authors:  Kruti Sheth Nair; Bruce Cheson
Journal:  Ther Adv Hematol       Date:  2016-02-03

2.  Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Susan O'Brien; Prithviraj Bose; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2017-01-27       Impact factor: 5.852

3.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

4.  BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Authors:  Alessandro Morotti; Cristina Panuzzo; Sabrina Crivellaro; Giovanna Carrà; Carmen Fava; Angelo Guerrasio; Pier Paolo Pandolfi; Giuseppe Saglio
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Inhibition of CK2 Reduces NG2 Expression in Juvenile Angiofibroma.

Authors:  Anne S Boewe; Silke Wemmert; Philipp Kulas; Bernhard Schick; Claudia Götz; Selina Wrublewsky; Mathias Montenarh; Michael D Menger; Matthias W Laschke; Emmanuel Ampofo
Journal:  Biomedicines       Date:  2022-04-21

6.  Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Authors:  Paul Brear; Darby Ball; Katherine Stott; Sheena D'Arcy; Marko Hyvönen
Journal:  J Med Chem       Date:  2020-10-29       Impact factor: 7.446

Review 7.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

Review 8.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

9.  The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.

Authors:  Hae J Chon; Kyoung J Bae; Yura Lee; Jiyeon Kim
Journal:  Front Pharmacol       Date:  2015-03-31       Impact factor: 5.810

Review 10.  Idelalisib for the treatment of chronic lymphocytic leukemia.

Authors:  Maliha Khan; Areeba Saif; Steven Sandler; Aibek E Mirrakhimov
Journal:  ISRN Oncol       Date:  2014-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.